Oncology

A recent study suggests multi-ancestry polygenic risk scores (PRS) may help refine active surveillance strategies for low- to intermediate-risk prostate cancer.

Selpercatinib, a targeted RET kinase inhibitor, has demonstrated continued efficacy in treating RET fusion-positive non–small cell lung cancer (NSCLC) even after disease progression.

A recent Phase II clinical trial has revealed promising results for men with low-grade prostate cancer on active surveillance (AS).

A new AI-powered model predicts outcomes for breast cancer patients on CDK4/6 inhibitors, offering precise insights into treatment response and enabling personalized care.

In this study, patients with a recurrence scores greater than 31 exhibited significant improvements in survival outcomes when treated with taxane and anthracycline-based chemotherapy.

Findings, presented at SABCS 2024, support tamoxifen as an effective adjuvant therapy for reducing recurrence in women with “good-risk” DCIS who opt to skip RT.

Avoiding chest wall irradiation post-mastectomy is safe for most intermediate-risk breast cancer patients, improving quality of care.

A novel deep learning-based radiomic biomarker could significantly enhance prediction of response to immune checkpoint inhibitors (ICIs) in patients with advanced non-small cell lung cancer (NSCLC).